Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 6.8% – Here’s Why

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) dropped 6.8% during trading on Thursday . The stock traded as low as $5.67 and last traded at $5.6280. Approximately 1,886,479 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 2,872,656 shares. The stock had previously closed at $6.04.

Analyst Ratings Changes

Several brokerages have weighed in on CMPX. Lifesci Capital initiated coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 price objective for the company. Wall Street Zen upgraded Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Compass Point set a $10.00 price objective on Compass Therapeutics in a research note on Monday, October 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. Finally, William Blair initiated coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Stock Down 4.2%

The firm has a 50 day simple moving average of $5.13 and a two-hundred day simple moving average of $3.99. The stock has a market capitalization of $1.03 billion, a P/E ratio of -12.86 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.06. On average, research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CMPX. Strs Ohio acquired a new stake in shares of Compass Therapeutics in the 1st quarter valued at approximately $34,000. Simplicity Wealth LLC lifted its stake in Compass Therapeutics by 81.8% in the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock valued at $220,000 after purchasing an additional 38,093 shares during the last quarter. Creative Planning acquired a new stake in Compass Therapeutics in the second quarter valued at approximately $30,000. XTX Topco Ltd acquired a new stake in Compass Therapeutics in the second quarter valued at approximately $84,000. Finally, Invesco Ltd. grew its stake in shares of Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after buying an additional 21,578 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.